Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-26-8 Purity >99.0% (HPLC) Nintedanib Esylate Intermediate Factory

Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) is an intermediate used to prepare Nintedanib Esylate (CAS: 656247-18-6). Nintedanib Esylate is a potent, oral triple angiokinase inhibitor developed by Boehringer Ingelheim that targets proangiogenic and pro-fibrotic pathways mediated by the vascular endothelial growth factor receptor, fibroblast growth factor receptor and plateletderived growth factor receptor families, as well as Src and Flt-3 kinases. Nintedanib Esylate was approved for the treatment of idiopathic pulmonary fibrosis (IPF), a condition in which the lungs become progressively scarred over time, by the US FDA in October 2014 and by the EMA in January 2015. The FDA granted nintedanib esylate fast-track, priority review, orphan product, and breakthrough designations. It was also approved by the EMA in November 2014 for treatment of non-small cell lung cancer in combination with docetaxel after first-line chemotherapy.